BioSight
Companies
Dyne Therapeutics, Inc. logo

DYN

NASDAQWALTHAM, MA
Dyne Therapeutics, Inc.

Dyne Therapeutics is a clinical-stage biotech company developing gene therapy programs, including its lead program DYNE-101 for rare neuromuscular diseases. The company operates under licensing agreements, including with the University of Mons, which provide access to intellectual property and technology for developing and commercializing product candidates, though these agreements carry risks related to termination, exclusivity, and disputes over rights and obligations.

Price history not yet available for DYN.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar